1. Introduction
===============

RNA-Seq exploits next-generation sequencing of cDNA for the study of gene expression. It has been applied to gain global views of the complexity of the transcriptome (Cloonan et al., [@B5]; Mortazavi et al., [@B15]; Ramsköld et al., [@B17]; Tang et al., [@B19]). In contrast to other profiling technologies, RNA-Seq can provide a comprehensive assay of gene expression that is not reliant on probes for targets that must be specified in advance. It is particularly well suited for the *de novo* discovery of exons and splice junctions, and it allows genome-wide qualitative expression profiling of organisms with unknown genome sequence.

Increasingly, there has been an interest in also applying RNA-Seq for the quantification of gene expression (Blow, [@B4]). While earlier work has focused on reads that unambiguously identify a transcript (Wilhelm et al., [@B22]), improved algorithms allow an extension of data analysis to complex gene models of alternative splicing, also taking into account the many reads that may come from different splice forms (Jiang and Wong, [@B7]). The discrimination of complex alternative splice forms is now possible with modern tools like *ERANGE* (Mortazavi et al., [@B15]), *ALEXA-seq* (Griffith et al., [@B6]), *NEUMA* (Lee et al., [@B11]), *IsoEM* (Nicolae et al., [@B16]), *RSEM* (Li et al., [@B13]; Li and Dewey, [@B12]), or *TopHat* + *Cufflinks* (Trapnell et al., [@B20], [@B21]).

In the popular *TopHat* + *Cufflinks* suite of tools, this is achieved by first aligning reads to the genome, with *de novo* discovery of exons and splice junctions (*TopHat*). Then this information is used to assemble transcripts and calculate their abundances in a second step (*Cufflinks*). *Cufflinks* can take advantage of reference gene model annotation for the quantification of known transcripts, omitting the transcript assembly step.

The *MapAl* tool presented here builds on this two-stage approach and extends the algorithm to already exploit gene models at the alignment step. Not having to identify novel splice forms for known genes considerably improves the assignment of reads to annotated transcripts, particularly for splice forms covered only by a small number of reads (Łabaj et al., [@B9]). This novel approach substantially increases the number of transcripts that can be measured reliably. That is of general interest because measurement precision determines the power of any subsequent analysis, such as the sensitive detection of differentially expressed transcripts, independent of whether replicates are employed or not (Anders and Huber, [@B2]).

2. Materials and Methods
========================

2.1. Data sources and annotation
--------------------------------

To validate the proposed approach, we consider two data sets representing different technologies, with different read lengths, read depths, sequencing strategies (single-end and paired-end), replicate type, and derived from different human cell lines.

### 2.1.1. Set 1

Three replicate measurements of mRNA extracted from a human HMEC 184A1 cell line culture were performed. With a total of 993 million 50 bp reads, corresponding to an entire ABI SOLiD-3+ flow cell *per* measurement sample, this constitutes one of the largest RNA-Seq data sets featuring technical replicates to date (measurements SRR413934, SRR413935, and SRR413936 from the PNNL-EMSL project with SRA-ID SRP011007).

### 2.1.2. Set 2

Three measurements from the now publicly available expression profiles of H1-hESC cell lines from the Wold/Caltech lab (experiments SRX026674, SRX026669, and SRX026685 from the [encode]{.smallcaps} project with SRA-ID SRP003497) were also examined. They provide 2 × 50 million of 75 bp paired-end reads *per* measurement, obtained using an Illumina Genome Analyzer II. While the measurements are not technical replicates, biological replicates of cell lines are sufficiently similar (in contrast to, say, patient samples) to allow a comparative study of processing approaches and their effects on measurement precision. The fact that we observe a similarly strong performance improvement in both data sets furthermore confirms this *post hoc*.

For an unbiased assessment of splice-form identification rate, we focused on reads aligned to the comprehensive 140,079 human transcripts annotated in EnsEMBL 58.

2.2. *MapAl* pipeline
---------------------

The performance of *MapAl* is demonstrated using the well established *TopHat* + *Cufflinks* programs as reference. Similar results were observed with alternative programs (data not shown).

In the standard *TopHat* + *Cufflinks* pipeline, annotated "gene models" are only used by the *Cufflinks* step (right-hand side, Figure [1](#F1){ref-type="fig"}A). *MapAl*, in contrast, allows the exploitation of gene models already at the alignment stage: Reads are directly aligned to the known transcript sequences (left-hand side, Figure [1](#F1){ref-type="fig"}B). *MapAl* next maps the aligned reads to genomic locations described by the corresponding "gene models" (box highlighted in bold), taking as an input a transcriptome mapped (SAM) file together with transcript annotations and produce a chromosome based SAM file. *Cufflinks* can subsequently be used for an estimation of transcript abundances (right-hand side).

![**Workflows for RNA-Seq expression profiling**. The established *TopHat* pipeline **(A)** is compared with the new *MapAl* approach **(B)**, which exploits gene models already at the alignment stage. Arrows indicate data flow -- alignments can be provided in SAM format (Sequence Alignment/Map), gene models in GTF (Gene Transfer Format), a refinement of the General Feature Format (GFF).](fgene-03-00028-g001){#F1}

Reads mapping to different splice forms of the same gene are reduced to one alignment, during *MapAl* processing when they match the same genomic location (Figure [2](#F2){ref-type="fig"}). On the other hand, different reads mapping to multiple targets are kept as distinct, matching different genomic locations.

![**Algorithm structure of *MapAl***. The flow chart presents the algorithmic structure of the *MapAl* pipeline. The steps executed by the *MapAl* script are marked by a dashed rounded rectangle. In particular, reads are first aligned to the known transcript sequences using any aligner supporting the SAM output format. They are then mapped to genomic locations by *MapAl* by means of the provided gene models. Alignment attributes embedded in the SAM format are adjusted according to strandedness. Then, for each read, alignments identical at the genome level are merged to produce the final genomic alignment file.](fgene-03-00028-g002){#F2}

We make that any read aligner supporting the SAM format can be used (Li and Homer, [@B14]). Here, RNA-Seq reads were aligned to the transcript sequences with *Bowtie* (Langmead et al., [@B10]). This facilitates a direct comparison of the tested pipelines because *Bowtie* is also used internally by *TopHat*. *Bowtie* v0.12.7 and *TopHat* v1.1.4 were run with settings suitable for the examined data set types (see [Appendix](#A1){ref-type="app"} for details).

2.3. Quantifying expression levels
----------------------------------

Expression levels were calculated using *Cufflinks* v0.9.1 (Trapnell et al., [@B21]) with EnsEMBL gene models provided as specified. For *de novo* only transcript discovery, EnsEMBL gene models were provided to *Cufflinks* in order to ignore all reads that could have come from known genes. Parameters were set for maximal sensitivity (`–min-frags-per-transfrag 1` and `-F 0`). When processing alignments in the *MapAl* pipeline, the option `-A 0` could also be set, as all parts of a read were known to originate from the same transcript sequence (this parameter is usually used to support reliable splice junction discovery through *TopHat*). For splice forms supported by less than one read alignment as assigned by *Cufflinks*, expression levels were set to zero. For a direct splice-form level comparison of *MapAl* and *TopHat* results, expression estimates had to be normalized by the total number of alignments considered at the respective *Cufflinks* step.

2.4. Measures of reproducibility
--------------------------------

For a systematic assessment of reproducibility, we can either consider the coefficient of variation (CV) on the linear scale, or the SD of log expression levels. For a number of reasons, gene expression data is typically analyzed on a log scale, on which differences in expression are examined by a *t*-test. Differences on the log scale then correspond to a fold-change on the linear scale. In this context, the appropriate measure of precision is the SD on the log scale. When referring to a relative error of 20% or less in the manuscript, we threshold the SD σ \< log~2~(120%) so that a value μ + σ compared to μ on the log~2~-scale corresponds to a relative error of 20% or less on the linear scale. We considered a transcript measured reliably if the relative error was less than 20%. The comparisons of reproducibility do not depend on this arbitrary threshold. Note that reproducibility also determines the power of statistics that operate without replicates (Anders and Huber, [@B2]).

It is noteworthy that many analyses considering replicate precision exclude measurements with no signal in any one of the replicates. This creates a methods bias toward a better perceived precision in the assay. In the examined Data Set 1, of all identified transcript targets, 14% had zero reads in one or two of the replicates but non-zero counts in the others, with 1--26 reads observed. These transcripts substantially contribute to the measurement noise at low expression levels, and consequently have to be counted toward the fraction of unreliable measurements. That approach is consistent because they have an infinite error on the log scale (and also the coefficient of variation on the linear scale is always \>80%).

3. Results
==========

We introduce *MapAl*, a novel approach for the quantification of transcript abundances from RNA-Seq data. We have validated our tool in comparison to the popular *TopHat* + *Cufflinks* analysis pipeline. In particular, we have considered the numbers of transcripts that could be identified and measured reliably. This was tested on two independent data sets representing alternative sequencing strategies and technologically different platforms.

3.1. Read mapping
-----------------

Read alignment statistics are shown in Table [1](#T1){ref-type="table"}. On one hand, the established pipeline with *TopHat* yielded up to 10% more mapped reads. This reflects the additional, unknown transcripts discovered by alignment to the genome sequence. The effect was particularly clear for Data Set 2, where paired-end reads could be exploited and *TopHat* was able to take advantage of the longer 75 bp reads, for which it was designed. In contrast, however, *MapAl* identified 2--3 times as many reads falling on known exon junctions, a consequence of making use of known splice-form sequences already at the alignment stage. Alignments to a typical transcript illustrate this point in Figure [A1](#FA1){ref-type="fig"} in Appendix. In the IGV browser window (Robinson et al., [@B18]), the blue boxes represent the second and third exons of ENST00000377403 (H6PD). The coverage band at the top indicates that reads entirely falling into exons are mapped identically by both *MapAl* (top) and *TopHat* (bottom). The difference is in the alignment of reads straddling splice junctions. In particular, for this exon structure, no reads spanning the exons one and two were identified by *TopHat*, whereas a substantial number was correctly mapped by *MapAl* (bridging the junction to the left of the browser window). Similarly, no reads spanning the exons three and four were identified by *TopHat*, whereas *MapAl* correctly identifies many reads spanning this region (bridging the junction to the right of the browser window). While some reads spanning the splice junction between exons two and three were found by *TopHat*, about twice as many such reads were identified by the *MapAl* pipeline. It is these reads mapping to exon junctions that often play a key role in identifying the expression of a particular splice form, and therefore determine both splice-form identification rate and transcript-specific measurement precision.

###### 

**Statistics of reads and mapping results**.

  Repl.                Reads   *TopHat*    *Bowtie* + *MapAl*               
  -------------------- ------- ----------- -------------------- ----------- -----
  **(A) DATA SET 1**                                                        
  1                    340     172 (51%)   18                   168 (50%)   45
  2                    341     170 (50%)   17                   167 (49%)   45
  3                    311     155 (50%)   16                   152 (49%)   41
  Total                993     497 (50%)   51                   487 (49%)   131

  Repl.                Read pairs   *TopHat*    *Bowtie* + *MapAl*              
  -------------------- ------------ ----------- -------------------- ---------- ----
  **(B) DATA SET 2**                                                            
  1                    49           36 (74%)    12                   31 (63%)   22
  2                    50           37 (73%)    12                   34 (67%)   25
  3                    50           36 (71%)    12                   33 (65%)   23
  Total                149          108 (72%)   35                   97 (65%)   70

*(A) Presents results for Data Set 1, whereas (B) shows the results for Data Set 2. Each row corresponds to one of the three replicate samples. Sums are displayed at the bottom of each table. All counts are given in millions, percentages are relative to the number of reads collected. The first group of columns gives results from mapping reads to the genomic sequence using *TopHat*. This is contrasted by the second group with results for *MapAl*, where reads are mapped to known transcript sequences using *Bowtie* and quantification is based on gene models explaining the alignments of these reads to the genome. Consistently for both data sets, while a slightly smaller amount of total reads was mapped, the number of reads hitting splice junctions increased two- to threefold*.

In addition we have examined the effects of providing *TopHat* known splice junctions *via* GTF a file (-G option) or through a junction list file (the -j option). Interestingly, this consistently increases the number of alignments falling on splice junctions by about 7%. Thus the remaining discrepancy can only be explained by particularities of the *TopHat* algorithm, such as the filtering of reads where the junction falls into a terminal region of the reads. We have also explored alternative *TopHat* parameter options (such as less restrictive -a and -F settings), yet the main picture remains, giving only a further 8% increase of the number of reads falling on junctions.

It also worth noticing that for *MapAl* about 80% of identified splice junctions were supported by more than 10 alignments. For *TopHat* that fraction was about 2/3, indicating that *MapAl* is not only able to identify more reads falling on splice junctions but also increases the support of identified splice junctions.

3.2. Reproducibility of quantitative expression profiling
---------------------------------------------------------

Table [2](#T2){ref-type="table"} compares the numbers of transcripts that could be identified and measured reliably. For Set 1 the *MapAl* pipeline found 101,169 splice forms versus the 87,649 identified by *TopHat* (72 vs 63% of all known transcripts). See [Appendix](#A1){ref-type="app"} for a detailed comparison.

###### 

**Statistics of identified and reliably measured transcripts**.

          *TopHat* + *Cufflinks*   *TopHat* + *Cufflinks* + models   *Bowtie* + *MapAl* + *Cufflinks* + models                                  
  ------- ------------------------ --------------------------------- ------------------------------------------- -------------- --------------- --------------
  Set 1   503,286 (--)             35,405 (--)                       87,649 (63%)                                39,116 (28%)   101,169 (72%)   56,980 (41%)
  Set 2   1,027,612 (--)           6,468 (--)                        97,570 (70%)                                15,288 (11%)   105,091 (75%)   21,091 (15%)

*For each analysis pipeline, the number of transcripts identified, as well as the number of transcripts that could be measured reliably are shown. The corresponding fractions of all known splice forms are displayed in brackets where applicable. Exploiting information about known splice forms much reduced measurement error and thus increased the number of transcripts assessed reliably (left to right). The first row is for Set 1 (3 × 300 mio 50 bp SOLiD reads). The improvements seen for Set 2 demonstrate that this applies even for experiments with biological replicates (3 × 50 mio 2 × 75 bp Illumina GA II paired reads)*.

Even more pronounced performance differences emerge when we consider only reliably measured splice forms: The standard *TopHat* + *Cufflinks* pipeline, including *de novo* discovery of alternative splice forms and genes, could assess 35,405 splice forms with a relative error \<20%. Interestingly, making use of known gene models increased the number of reliably measured transcripts to 39,116, even though these now include only known genes and splice forms.

Using *MapAl*, however, the expression levels of 56,980 transcripts could be measured reliably -- obtaining an improvement by almost 50% over the established workflow. Figure [3](#F3){ref-type="fig"} compares the distributions of measurement errors. On one hand, the maximum errors are larger for *TopHat* (red curves, extending further to the right). On the other hand, a larger number of transcripts could be measured with low errors by *MapAl* (black curves plotting higher values on the *y*-axes to the left of the dashed lines). The dashed lines indicate measurement errors of 20%. These observations equally hold for the technical replicates of Data Set 1 and the biological replicates of Data Set 2 (which exhibit higher variation in general).

![**Distribution of measurement errors**. Each of the plots compares the distributions of measurement errors for *TopHat* (red line) and *MapAl* (black line). The *x*-axis shows the SD across three replicate measurements on the log scale. The dashed vertical line marks an error of 20%. The *y*-axis represents the number of splice forms that could be measured with a certain precision (scaled to an arbitrary unit allowing a comparison across samples). The first panel displays results for Data Set 1 \[**(A)** technical replicates\], the second panel is for Data Set 2 \[**(B)** biological replicates\].](fgene-03-00028-g003){#F3}

It is noteworthy that the 56,980 known transcripts that could be measured reliably can easily be complemented by measurements for newly discovered genes, adding another 11,288 transcripts, and bringing the total to 68,268 reliably profiled splice forms. This is almost twice as many as the 35,405 that could be assessed reliably with the standard pipeline, and similar improvements could be demonstrated for Data Set 2 (Table [3](#T3){ref-type="table"}).

###### 

**Statistics of identified and reliably measured transcripts, adding genes identified *de novo***.

          *Bowtie* + *MapAl* + *Cufflinks* + models   *TopHat* + *Cufflinks* (*de novo*)   Together (models + *de novo*)                      
  ------- ------------------------------------------- ------------------------------------ ------------------------------- -------- --------- --------
  Set 1   101,169                                     56,980                               164,138                         11,288   265,307   68,268
  Set 2   105,091                                     21,091                               367,383                         3,579    472,474   24,670

*The left-most column of  Table [2](#T2){ref-type="table"} includes results for both known transcripts and genes identified *de novo*. Restricting the pipeline to known splice forms and making use of known splice form sequences as much as possible has considerably increased the number of transcripts that can be assessed reliably. These statistics are shown again in the left-most column of this table. We can now consider adding genes identified only *de novo*. Statistics for these genes are shown in the middle column. Taken together, we can achieve the most powerful analysis, namely combining the output of the \[*Bowtie* + *MapAl* + *Cufflinks* + models\] pipeline with the additional results from \[*TopHat* + *Cufflinks* (*de novo*)\]*.

As it is always interesting to compare the performance of alternative pipelines, *MapAl* has been constructed for an easy combination with other tools that support the SAM format, supporting future developments and further independent benchmarks.

3.3. Comparison of execution times
----------------------------------

Collected data sets getting even bigger, it is of interest to asses the execution time of the analyzed pipelines. The examined approaches considered a similar number of alignments, thus giving similar running times for the *Cufflinks* step. As this step is fast compared to the overall running time of the pipeline, we can focus on the remaining steps, comparing *Bowtie* + *MapAl* and *TopHat*.

As *MapAl* performance was disk bound, parallelization did not yield a considerable speed-up. Thus *MapAl* was run in single-thread mode, however, parallel analysis of reads aligned to transcripts for each chromosome is worth further consideration. Note that the performance of the file system may easily become the limiting factor in overall throughput.

Table [4](#T4){ref-type="table"} presents averaged execution times for both pipelines. For Data Set 1, featuring shorter, single-end reads, the *MapAl* pipeline executed over five times faster than established *TopHat* + *Cufflinks*. For Data Set 2, *MapAl* was almost twice faster, despite two factors working to the advantage of the established tools: (1) *TopHat* was designed and optimized for the longer 75 bp reads, and (2) each pair of reads is treated as a "one fragment" by *TopHat*, while both reads are processed independently by *MapAl*, doubling the effective number of sequences that have to be considered.

###### 

**Comparison of pipeline execution times**.

  Data    Technology                        Reads/read pairs   *TopHat*      *Bowtie* + *MapAl*
  ------- --------------------------------- ------------------ ------------- --------------------
  Set 1   50 bp single-end ABI SOLiD-3+     330                130 h         23 h 30 min
  Set 2   75 bp paired-end Illumina GA II   50                 11 h 30 min   7 h 40 min

*For each data set, the table compares average execution times for both pipelines. Values were averaged across replicates. Tools were run on a typical modern workstation equipped with 2× Intel E5520 2.26 GHz (allowing up to 16 threads). The machine had 42 GB of RAM, and data was accessed *via* NFS on a 12-disk RAID-6. To take advantage of execution parallelization, *Bowtie* and *TopHat* were run as recommended allowing up to 15 worker threads in addition to the manager thread (`-p 15`)*.

4. Discussion
=============

Whereas taking advantage of known transcript sequences at the alignment stage and simultaneously discovering new alternative splice forms of known genes will require the development of extended models for the estimation of transcript levels, *MapAl* builds on existing tools to provide a fast and straightforward solution for quantitative expression profiling by RNA-Seq.

It supports both users and further development by giving a free choice of combining alternative steps at different stages of the process. In particular, a wide range of read mappers supporting the standard SAM format can be employed, because *MapAl* also handles indels correctly. Indels are the most frequent form of sequencing error (Albers et al., [@B1]) but can also play an important role in variant discovery (Krawitz et al., [@B8]).

For this manuscript, the software has been validated on data from single-end reads generated by a stranded RNA-Seq protocol (SOLiD, Data Set 1), and on data from paired-end reads generated by an unstranded RNA-Seq protocol (Illumina, Data Set 2). We are now extending the tool to support single-end, paired-end, and mate-pair reads from both stranded and unstranded RNA-Seq protocols.

We are also improving the handling of exon junctions. With few exceptions, exons are longer than 50 nucleotides (Berget, [@B3]). Therefore, reads spanning more than two exon junctions have been very rare for early next-generation sequencing data, with typical read lengths as short as 36 bp. Current equipment already produces 150 bp reads. With read lengths of modern platforms ever increasing, reads spanning multiple splice junctions are becoming a more frequently observed issue. As these reads are particularly powerful in the discrimination of specific splice forms, we are adding full support for reads that span multiple junctions.

The next release of our software implementing these features will become available on <http://www.bioinf.boku.ac.at/pub/MapAl/early> March 2012, and will also support the latest version of *Cufflinks* (Jan 2012), taking advantage of recent features like the improved multi-mapped read correction that has been introduced last year.

In summary, *MapAl* provides a flexible, modular approach to quantitative expression profiling by RNA-Seq, building on the strengths of popular established tools. It implements advanced features dealing with challenges in read alignment to support the analysis needs of the latest sequencing platforms. In particular, it takes advantage of splice-form sequence information already at the alignment stage. *MapAl* increases the number of reliably measured known transcripts by about 50% and also allows the profiling of new genes, in total *almost doubling* the number of transcripts that can reliably be assessed.

Note Added in Proof
===================

With version 1.4.0 released this year, *TopHat* can now also map reads directly to the transcriptome, exploiting ideas similar to the approach first introduced in Łabaj et al. ([@B9]). Initial comparisons with *MapAl*, however, suggest considerable differences in resulting expression level estimates, apparently due to additional heuristics and different implementation details. In view of the substantial effects of selecting one program over another, further comparative studies of alternative tools are certainly of interest. The modular approach of *MapAl* gives users a valuable choice, allowing an easy combination of its efficient two-stage mapping strategy with established options, like *Bowtie* and *Cufflinks*, but also working directly with other tools supporting the SAM format.

Availability and Implementation
===============================

The *MapAl* suite is available for download under the GPL at [www.bioinf.boku.ac.at/pub/MapAl](www.bioinf.boku.ac.at/pub/MapAl)
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*Bowtie* and *TopHat* execution parameters
==========================================

To facilitate a direct comparison of the established *TopHat* pipeline with the new approach implemented in *MapAl* we have used *Bowtie* as an aligner because it is also used by *TopHat*. To make sure that the comparison is as fair as possible we run *Bowtie* with the settings used internally by the *TopHat* tested (v1.1.4).

For Data Set 2 (Illumina), *TopHat* runs *Bowtie* with the following parameters:

    bowtie -q –un TopHat1/tmp/left_kept_reads_
    missing.fq \
    –max/dev/null -n 2 -p 15 -k 40 -m 40

As we are not interested in separate reports about not aligned reads and reads aligning to too many locations we specify options `–max` and `–un` to drop these. The `-S` switch requests output of alignments in SAM format:

    bowtie -q -n 2 -p 15 -k 40 -m 40 -S

For Data Set 1 (ABI SOLiD, colourspace), *TopHat* runs *Bowtie* with the following parameters:

    bowtie -q -C –col-keepends –un \
    TopHat1/tmp/left_kept_reads_missing.fq
    –max \
    /dev/null -n 2 -p 15 -k 40 -m 40

Because the original files of this data set are provided in .*fastc* and .*qual* formats, we change `-q` to `-f`. Again, we drop `–max` and `–un` and add `-S` to select the required output files and formats, yielding:

    bowtie -f -C –col-keepends -n 2 -p 15 -k
    40 -m 40 -S

Users might want to consider increasing the values for the `-k` and `-m` parameters while aligning directly to the transcriptome in order to allow more correct hits to be reported, as large numbers of such hits can be expected for complex splice-form structures.

Detailed comparison of expression level estimates from the two pipelines
========================================================================

*MapAl* identifies additional reads spanning exon junctions. We here discuss the differences in expression level estimates that are observed as a result. Comparative scatter plots for individual replicates are presented in Figure [A2](#FA2){ref-type="fig"}. For each transcript, the *x*-axes show the *MapAl* expression level in comparison to the *TopHat* expression level on the *y*-axes, each on a log~10~ scale. Darker gray levels indicate a higher number of transcripts. Note that we plot transcripts with no expression call at --5 in order to also visualize differences in presence calls.

First, consider the simple gene models of Figure [A3](#FA3){ref-type="fig"}A. At sufficient coverage, it is possible to assess the expression of both splice forms even without reads spanning exon junction. Adding read alignments that fall on splice junctions will therefore slightly increase the coverage at exon boundaries and thus increase the respective expression levels. This contributes to the observation in the scatter plots (Figure [A2](#FA2){ref-type="fig"}), that the expression levels for *MapAl* are in general higher (densities below the diagonal).

Larger differences can already be expected for the simple gene model of Figure [A3](#FA3){ref-type="fig"}B. Consider a scenario where no reads spanning exon 2 could be identified by *TopHat*, as shown in the plot of a hypothetical coverage at the top of the panel. This can happen particularly easily for shorter exons. In that case, the evidence seems to suggest that splice-form T1 was clearly expressed whereas there is a lack of specific evidence for an expression of T2. Adding read alignments that cover the splice junctions between exons 1 and 2 or exons 2 and 3 changes the picture. One may even reach the opposite conclusion, namely, that splice-form T2 was expressed whereas T1 was not, if there is a sufficient number of these reads. In such extreme cases, a difference in presence calls will be observed (Table [A1](#TA1){ref-type="table"}). These contribute to the densities parallel to an axis in the scatter plots.

Generally, if both splice forms were expressed, one expects additional read alignments that cover the splice junctions between exons 1 and 3, providing specific evidence for the expression of splice-form T1, and also additional read alignments that cover the splice junctions between exons 1 and 2 or exons 2 and 3, providing specific evidence for the expression of splice-form T2. In that case, the *MapAl* expression level for T1 will be lower (contributing to the density above the diagonal). In contrast to *TopHat*, *MapAl* can however make a presence call for T2, contributing to the horizontal density in the scatter plot. This explains why the density indicating presence calls unique to *MapAl* (horizontal), has a larger volume than the density indicating presence calls unique to *TopHat* (vertical). The scatter plots thus reflect that *MapAl* consistently identifies more transcripts. Table [A1](#TA1){ref-type="table"} gives a detailed comparison.

More complex effects can be understood using the gene model of Figure [A3](#FA3){ref-type="fig"}C as an example. Consider the scenario where no reads spanning exon junctions could be identified by *TopHat*, as shown in the plot of a hypothetical coverage at the top of the panel. With no evidence for the specific expression of the different splice forms, reads are evenly assigned. Additional evidence from alignments falling on splice junctions plays a critical role in assessing the specific splice-form expression levels. In a common case, reads covering exon junctions support the dominant expression of a particular splice-form. Taking this evidence into account will therefore boost the *MapAl* expression level estimate for this splice-form, while depressing the expression level estimates for the others. This change is smaller as it is spread across multiple splice forms. That explains why the deviations below the diagonal in the scatter plots comparing *MapAl* and *TopHat* are stronger. In fact, depending on the data set and replicate considered, expression levels for *MapAl* were higher for 38%--42% of all known transcripts, and higher for *TopHat* for 13%--17% (Table [A2](#TA2){ref-type="table"}).

In summary, the correct consideration of reads spanning splice forms in *MapAl* can affect expression estimates considerably.

![**Alignments to a typical transcript**. The figure shows an IGV browser window (Robinson et al., [@B18]). The blue boxes represent the second and third exons of ENST00000377403 (H6PD). The gray coverage band at the top reflects that reads entirely falling into exons are mapped identically by both *MapAl* (top) and *TopHat* (bottom). The difference is in the alignments of reads straddling splice junctions.](fgene-03-00028-a001){#FA1}

![**Scatter plot of transcript expression levels**. Scatter plots present relation between transcript expression assessed by *Cufflinks* for *TopHat* pipeline (*y*-axis) and *MapAl* pipeline (*x*-axis). The left column presents scatter plots of three replicates of Data Set 1, the right column presents scatter plots of three replicates of Data Set 2. From all scatter plots it is clear that substantial amount of transcripts are higher expressed for *MapAl* pipeline than for *TopHat* one.](fgene-03-00028-a002){#FA2}

![**Exemplary gene models**. Schematic diagrams presents three example gene models. The top row displays a hypothetical coverage assuming a uniform distribution of reads falling entirely within the exons. The models **(A--C)** exhibit increasing complexity. In the first model, it is still possible to assess the expression of alternative splice forms even without reads covering exon junctions. Additional junction spanning reads will moderately affect expression level estimates. In the next model, adding read alignments that fall on splice junctions can already considerably affect presence calls and estimates of specific splice-form expression levels. In the most complex model, adding read alignments that fall on splice junctions plays a critical role in assessing the specific splice-form expression levels. In this scenario additional evidence will boost the expression level estimate for the dominant splice-form, while depressing the expression level estimates for the others.](fgene-03-00028-a003){#FA3}

###### 

**Comparison of presence calls**.

  Data Set   Replicate   *TopHat* (%)   *MapAl* (%)   In both (%)   *TopHat* only (%)   *MapAl* only (%)
  ---------- ----------- -------------- ------------- ------------- ------------------- ------------------
  1          1           54.5           67.4          51.1          3.3                 16.2
             2           54.6           67.3          51.2          3.3                 16.0
             3           54.2           67.1          50.9          3.2                 16.1
  2          1           51.8           62.1          46.6          5.3                 15.5
             2           52.1           64.2          47.2          4.9                 17.0
             3           52.2           64.6          47.4          4.7                 17.1

*For each data set and each replicate, the table shows the number of known splice forms identified by *TopHat* and *MapAl*. The majority of splice forms is seen by both pipelines. Additional reads spanning exon junctions, however, provide additional evidence for or against the presence of specific splice forms in *MapAl*, resulting in the differences observed*.

###### 

**Comparison of expression level estimates**.

  Data Set   Replicate   *MapA1* \> *TopHat* (%)   *MapA1* ∼ *TopHat* (%)   *MapA1* \< *TopHat* (%)
  ---------- ----------- ------------------------- ------------------------ -------------------------
  1          1           41.8                      45.6                     12.6
             2           41.7                      45.6                     12.7
             3           41.6                      45.8                     12.6
  2          1           38.4                      44.7                     16.9
             2           39.4                      43.6                     17.0
             3           40.3                      43.1                     16.6

*For each data set and each replicate, the table shows the number of known splice forms for which *MapAl* and *TopHat* yield similar expression levels and for how many splice forms expression levels deviated by more than 20%. The statistics include splice forms without presence call from one or both of the pipelines*.
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